spot_imgspot_img

FDA approves 2nd over-the-counter drug to treat opioid, fentanyl overdoses

The U.S. Food and Drug Administration approved a second over-the-counter drug to combat opioid overdoses, including those caused by fentanyl.

RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray was approved as the second over-the-counter (OTC), nonprescription nasal spray for the treatment of a known or suspected opioid overdose. When the drug will be available and its cost to consumers will be determined by its manufacturer, Harm Reduction Therapeutics.

“We know naloxone is a powerful tool to help quickly reverse the effects of opioids during an overdose. Ensuring naloxone is widely available, especially as an approved OTC product, makes a critical tool available to help protect public health,” FDA Commissioner Robert M. Califf, M.D., said in a statement. “The agency has long prioritized access to naloxone products, and we welcome manufacturers of other naloxone products to discuss potential nonprescription development programs with the FDA.”

More than 105,000 fatal overdoses were reported from March 2022 to February 2023, the FDA reported, “which were primarily driven by synthetic opioids like illicit fentanyl.”

Harm Reduction Therapeutics, a 501(c)(3) nonprofit pharmaceutical company, was founded in 2017 “to save lives by making naloxone available over-the-counter for free or at the lowest possible cost. Free from a profit motive, with investors and partners committed to our life-saving mission, our goal is to launch an FDA-approved product as soon as possible,” it states on its website.

The announcement comes after the FDA in March approved Narcan/Naloxone for over the counter use, the brand and generic versions of the medication that’s been found to rapidly reverse the effects of opioid overdoses if administered quickly enough. Naloxone has become the standard treatment for opioid overdoses among law enforcement, emergency response technicians, addiction treatment and medical professionals.

Harm Reduction Therapeutics says that Naloxone has successfully reversed overdoses in 98.8% of cases evaluated by the CDC and that tens of thousands of lives have been saved by it.

Its application for RiVive nasal spray for nonprescription use was approved after data it submitted “showed similar levels of RiVive reach the bloodstream as an approved prescription naloxone product,” the FDA said. It also said the nonprofit demonstrated that the drug was safe and effective for use as described in its labeling and that consumers understood how to use it without a health-care professional.

The FDA also this month approved another new drug, sANDA, as the first generic nonprescription naloxone nasal spray product to be available on the market. The application was filed by Padagis US LLC, an Israeli pharmaceutical company, requesting approval to change its prescription marketing status to over the counter marketing status.

Fentanyl remains the No. 1 killer of Americans ages of 18 and 45. According to data analyzed by Families Against Fentanyl, children under 14 are dying at a faster rate from illicit fentanyl poisoning than any other age group.

Recognizing the lethality of the drug, all 50 states and the District of Columbia already have “access laws or alternate arrangements in place that allow persons to obtain naloxone from a pharmacist without an individualized, in-person prescription,” Narcan.com reports.

The majority of states and the District of Columbia also have Naloxone standing orders, which allow adults to purchase the drug from a licensed pharmacy without a prescription, Rehabs.org explains. Most rehab facilities and state health departments also have programs through which Americans can get Naloxone for free.

Here’s how Americans can get it.

The OTC status gives consumers more options to purchase the drug including at convenience stores, grocery stores, gas stations and online, the FDA said.

DON’T MISS OUT

Be the first to know about the latest news, giveaways, events, and updates from The Black Chronicle!

We don’t spam! Read our privacy policy for more info.

spot_imgspot_img
spot_img

Hot this week

African and Caribbean Nations Call for Reparations for Slave Trade, Propose Global Fund

Nations across Africa and the Caribbean, deeply impacted by...

Health care company agrees to pay $22.5 million to settle claims of over billing

A health care company agreed to pay nearly $22.5...

Sports betting expert offers advice on paying taxes for gambling winnings

(The Center Square) – Tax season is underway, and...

Entertainment district benefits don’t outweigh the cost, economists say

(The Center Square) — Weeks later, after more details...

Business association ‘disappointed’ by WA L&I’s proposed workers comp rate hike

(The Center Square) – The Association of Washington Business...

Calcasieu River Bridge in design phase, construction to begin in 2026

(The Center Square) – Louisiana's District 7 in the...

Jury selection for Madigan trial pushes into next week

(The Center Square) – Jury selection is not complete...

Transgender women participation in sports debated by Georgia Senate

(The Center Square) – A Georgia Senate committee meeting...

Arizona Democrats call for audit over nearly lost Title I funds

(The Center Square) – Arizona Senate Democrats are still...

Students for Justice in Palestine no longer recognized at U of Illinois

(The Center Square) – The University of Illinois Urbana-Champaign...

Spokane spent $43K on campaign for tax hike; might balance deficit with reserves

(The Center Square) – Records show Spokane put nearly...

Trump asks judge to delay releasing evidence in D.C. election interference case

Former President Donald Trump on Thursday asked a federal...

Groups split over Wisconsin ballot measure preventing non-citizens from voting

(The Center Square) – Opponents of Wisconsin’s November ballot...

More like this
Related

Calcasieu River Bridge in design phase, construction to begin in 2026

(The Center Square) – Louisiana's District 7 in the...

Jury selection for Madigan trial pushes into next week

(The Center Square) – Jury selection is not complete...

Transgender women participation in sports debated by Georgia Senate

(The Center Square) – A Georgia Senate committee meeting...

Arizona Democrats call for audit over nearly lost Title I funds

(The Center Square) – Arizona Senate Democrats are still...